UICC

Global Smart Ticketing Market Outlook to 2026: Rambus, Softjourn, Vix Technology and Conduent Dominate

Retrieved on: 
Thursday, December 23, 2021
Titan, Mastercard, EMV, Rail Delivery Group, State bank, RFID, Technology, Visa, NFC, Garmin, City, USD, ETC, Rambus, United Kingdom, SBI, Lists of video games, Fitbit, Apple Pay, Tourism, Industry, Sport, Pedestrian, Travel, UICC, COVID-19, Rio, Samsung, RDG, QR, American football, POS, Infineon Technologies, Samsung Pay, Traction, State Bank of India, CAGR, Adoption, Transport, Online shopping, Mobile phone, Gemalto, Growth, Calypso

The global smart ticketing market was valued at USD 12.36 billion in 2020, and it is expected to reach USD 25.33 billion by 2026, registering a CAGR of 12.9%, during the period of 2021-2026.

Key Points: 
  • The global smart ticketing market was valued at USD 12.36 billion in 2020, and it is expected to reach USD 25.33 billion by 2026, registering a CAGR of 12.9%, during the period of 2021-2026.
  • Smart ticket, as a substitute to the traditional paper-based ticketing, gained traction in recent times, owing to the emphasis on the digitization of ticketing processes.
  • Technological advancements in smart ticketing have propelled businesses to adopt technologies like RFID, NFC, QR code, and barcode in Germany.
  • The rise of smartphones equipped with NFC technology has introduced the necessary infrastructure for smart ticketing across the industries in the region.

Sequans Introduces New 4G/5G Cellular IoT Modules Based on its Second-Generation Cat 1 Calliope 2 Chip

Retrieved on: 
Wednesday, December 15, 2021
Technology, SIM, Solution, CES, Cat, Growth, NYSE, IOT, Human, 3GPP, MCU, Adoption, NB, Data-rate units, Head, UICC, SVP, LTE-M, ISIM, Renesas Electronics, DL, LTE, CAT1, TSR, Voice over LTE, Eye, Twitter, Taurus, Partnership, Mobile phone, Narrowband IoT

Calliope 2 GC02S1 modules are optimized to support three regional variants covering North America, Japan, and Europe.

Key Points: 
  • Calliope 2 GC02S1 modules are optimized to support three regional variants covering North America, Japan, and Europe.
  • Advancements in Sequans' Calliope 2 chip technology remove the cost and power consumption barriers that have thus far limited widespread adoption of Cat 1 for IoT.
  • "Therefore, we are excited about Sequans's Calliope 2 Cat 1 platform that supports IoT use cases demanding higher bandwidth, greater mobility, and lower latency."
  • Sequans Communications S.A. (NYSE: SQNS) is a leading developerand supplierofcellular IoT connectivity solutions, providing chips and modules for5G/4G massive and broadband IoT.

FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer

Retrieved on: 
Friday, October 15, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, ROG, Death, Immune system, Lung, PD-L1, PD-1, Safety, Lung cancer, FDA, Disease, Pneumonitis, Regulation of tobacco by the U.S. Food and Drug Administration, Fever, American Cancer Society, Paclitaxel, Patient, Carboplatin, Platinum, Risk, Cancer, Tissue, Hoffmann-La Roche, Breast, Phase, Food, NSCLC, ITT, Immunotherapy, Hope, Human, BSC, Diagnosis, Etoposide, Treatment of lung cancer, Physician, PD, United Kingdom, Skin, Neoplasm, UICC, Bevacizumab, RO, Pneumonia, Head, Toxicity, SCLC, Recurrence, DFS, Review, Pharmaceutical industry, Medical imaging, Vaccine, Health insurance, Uranium, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the U.S.

Key Points: 
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the U.S.
  • In addition to becoming the first approved cancer immunotherapy for adjuvant NSCLC, Tecentriq was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy).
  • According to the American Cancer Society, it is estimated that more than 235,000 Americans will be diagnosed with lung cancer in 2021.
  • Today, about half of all people with early lung cancer still experience a cancer recurrence following surgery.

New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer

Retrieved on: 
Monday, September 20, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ITT, Safety, Food, Oncology, Nominal interest rate, Neoplasm, Breast, WCLC, RO, Treatment of lung cancer, Carboplatin, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Recurrence, Congress, Conference, SCLC, FDA, Guideline, Cancer, Lung cancer, Hoffmann-La Roche, European Society for Medical Oncology, Population, ROG, Head, Immune system, DFS, Phase, NSCLC, Death, Stage, International Association, PD-1, Large-cell lung carcinoma, Paclitaxel, Disease, Risk, Bevacizumab, PD, BSC, Priority review, American Cancer Society, Etoposide, PD-L1, Tissue, Platinum, ESMO, UICC, Skin, Lung, Pharmaceutical industry, Health insurance, Medical imaging, Uranium, Vaccine, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

Key Points: 
  • Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
  • IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning.
  • The data presented at ESMO and WCLC further contribute to our understanding of Tecentriq in this treatment setting.
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world.

IMpower010 Shows Significantly Improved Disease-free Survival for Patients with Resected Stage II to III Non-Small Cell Lung Cancer

Retrieved on: 
Saturday, September 11, 2021

The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients with stage II-IIIA (UICC v7) non-small cell lung cancer.

Key Points: 
  • The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients with stage II-IIIA (UICC v7) non-small cell lung cancer.
  • The primary endpoint of investigator-assessed disease-free survival was tested hierarchically in the PD-L1 TC 1% (SP263) stage II-IIIA population, all-randomized stage II-IIIA population, and ITT population (stage IB-IIIA).
  • "Patients who participated in the IMpower010 trial, including patients with nodal involvement, saw benefit across disease stages (stage II-IIIA sub-populations)," Altorki reported.
  • The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe.

More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride

Retrieved on: 
Wednesday, September 8, 2021
Other Health, Sports, General Health, Pharmaceutical, Philanthropy, Oncology, Fund Raising, Foundation, Biotechnology, Other Philanthropy, Biking, Cycling, Health

I try to give back where I can, for every patient who may need the breakthroughs that come from cancer research.

Key Points: 
  • I try to give back where I can, for every patient who may need the breakthroughs that come from cancer research.
  • The money raised is matched dollar-for-dollar by Bristol Myers Squibb, with a maximum donation of up to $500,000.
  • Since then, more than 530 Bristol Myers Squibb employees have volunteered their personal time to fundraise and extensively train for the ride, resulting in more than $7.15 million for cancer research.
  • In addition to Coast 2 Coast 4 Cancer in the U.S., the Bristol Myers Squibb global workforce demonstrates its long-standing commitment to cancer research with Country 2 Country 4 Cancer (Europe).

Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer

Retrieved on: 
Tuesday, August 24, 2021
Research, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Company, Union, University, Medicine, Biochemistry, TCG, Cancer, Life, University of Texas Southwestern Medical Center, Protein, Cell biology, CSO, Collection, Lists of diseases, Science, Merck, SECA, Drug discovery, Howard Hughes Medical Institute, Lux Capital, Coronavirus Scientific Advisory Board (Turkey), Disease, Doctor of Philosophy, Health, AUM, Metabolism, Union for International Cancer Control, Inflammation, Multimedia, Silicon, Pediatrics, Bio, Patient, CEO, Organization, Scientific Advisory Group for Emergencies, Lux, UICC, Oncology, Technology, Scale Venture Partners, Pharmaceutical industry, Medical device, Atavistik Bio, The Column Group, Lux Capital, Nextech Invest, Ltd., ATAVISTIK BIO, THE COLUMN GROUP, LUX CAPITAL, NEXTECH INVEST, LTD.

View the full release here: https://www.businesswire.com/news/home/20210824005342/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210824005342/en/
    John A. Josey, PhD, Acting CEO of Atavistik Bio, and Marion Dorsch, PhD, President and CSO.
  • The Company will be helmed by John A. Josey, PhD, Acting CEO of Atavistik Bio, who was formerly CEO at Peloton Therapeutics, which was acquired by Merck in 2019.
  • We are delighted to gain the support of such an esteemed collection of venture investors in our quest to find first-in-class drug compounds in metabolic diseases and cancer.
  • Atavistik was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism.